TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade
Yuki Tanaka1, Hiroshi Wada2, Risa Goto2
1Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki, Japan. yuuki-tanaka@taiho.co.jp.
Abstract:
Cancer peptide vaccines are a promising cancer immunotherapy that can induce cancer-specific cytotoxic T lymphocytes (CTLs) in tumors. However, recent clinical trials of cancer vaccines have revealed that the efficacy of the vaccines is limited. Targeting single antigens and vaccination with short peptides are partly the cause of the poor clinical outcomes. We synthesized a novel multi-epitope long peptide, TAS0314, which induced multiple epitope-specific CTLs in HLA knock-in mice. It also showed superior epitope-specific CTL induction and antitumor activity. We also established a combination treatment model of vaccination with PD-1/PD-L1 blockade in HLA-A*2402 knock-in mice, and it showed a synergistic antitumor effect with TAS0314. Thus, our data indicated that TAS0314 treatment, especially in combination with PD-1/PD-L1 blockade, is a promising therapeutic candidate for cancer immunotherapy.
Insights
A novel multi-epitope peptide vaccine, TAS0314, effectively induces cancer-specific T cells and shows enhanced antitumor activity. Combination therapy with PD-1/PD-L1 blockade further boosts its therapeutic potential in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Cancer peptide vaccines aim to induce cytotoxic T lymphocytes (CTLs) for tumor eradication.
- Limited clinical efficacy of current cancer vaccines is linked to targeting single antigens and short peptides.
Purpose of the Study:
- To develop and evaluate a novel multi-epitope long peptide vaccine (TAS0314) for enhanced cancer immunotherapy.
- To assess the synergistic antitumor effect of TAS0314 in combination with PD-1/PD-L1 blockade.
Main Methods:
- Synthesis of a multi-epitope long peptide vaccine, TAS0314.
- Evaluation of CTL induction and antitumor activity in HLA knock-in mouse models.
- Establishment of a combination treatment model with PD-1/PD-L1 blockade.
Main Results:
- TAS0314 successfully induced multiple epitope-specific CTLs in mice.
- The novel vaccine demonstrated superior epitope-specific CTL induction and antitumor efficacy.
- Combination therapy with TAS0314 and PD-1/PD-L1 blockade exhibited synergistic antitumor effects.
Conclusions:
- TAS0314 represents a promising advancement in cancer peptide vaccine design.
- Combination of TAS0314 with PD-1/PD-L1 blockade offers a potent strategy for cancer immunotherapy.
